TX45 APEX Phase 2 patient enrollment in PH-HFpEF is nearing completion with topline results anticipated in late Q4 2026 or early Q1 2027TX2100 advanced into Phase 1a healthy volunteer clinical trial in February 2026 as a potential treatment for Hereditary Hemorrhagic Telangiectasia ("HHT"), and as of April 2026, four cohorts have been dosed with topline results expected by the end of Q3 2026TX45 ALPINE Phase 2 clinical trial initiated in Pulmonary Hypertension in Heart Failure associated with Interstitial Lung Disease ("PH-ILD," Group 3 PH), with first site activated in February 2026 and screening initiated in March 2026, expanding TX45 into a second pulmonary hypertension indicationStrength

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed Jessica Chutter to its Board of Directors, effective June 8, 2026. Ms. Chutter brings more than four decades of experience in global healthcare investment banking, with deep expertise advising biotechnology and pharmaceutical companies on strategic positioning, mergers and acquisitions, and capital markets execution. She is widely recognized as a pioneer in investment

WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2026. TD Cowen 46th Annual Health Care Conference  Date:March 4, 2026Time:11:10 AM ESTLocation:Boston, MAFormat:Fireside ChatPresenters:Alise Reicin, MD, President and Chief Executive OfficerWebcast:Link  Leerink Global Healthcare Conference  Date:March 11, 2026Time:1:40 PM ESTLocation:M

Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH-HFrEF") in October 2025. Topline results showed TX45 was well tolerated and improved both left heart function and pulmonary hemodynamics in patients with Group 2 PH-HFrEFTX2100 advanced into Phase 1a healthy volunteer clinical trial, randomizing the first subject in February 2026, as a potential treatment for Hereditary Hemorrhagic Telangiectasia ("HHT")TX45 advanced into Phase 2 clinical trial in February 2026 with first site activated and opened for screening patients with Pulmonary Hypertension associate

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), announced that it will host a virtual key opinion leader (KOL) event and TX2100 discussion on Tuesday, February 24, 2026 from 11:00 a.m. to 12:30 p.m. ET. The event will feature Hanny Al-Samkari, MD (Massachusetts General Hospital, Harvard Medical School), who will join company management. During the event, the management team will review the target, mechanistic rationale, and preclinical evidence sup

WATERTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in December 2025. Piper Sandler 37th Annual Healthcare Conference Date:Time:Location:Format:Presenters:Webcast:December 2, 20253:30 PM ESTNew York, NYFireside ChatAlise Reicin, MD, President and Chief Executive OfficerLink Evercore 8th Annual Healthcare Conference Date:Location:Format:December 3,

Positive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH-HFrEF")Expect to initiate TX2100 Phase 1 clinical trial in healthy volunteers in Q1'2026 as a potential treatment for Hereditary Hemorrhagic Telangiectasia ("HHT")TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45's safety and hemodynamic effects in patients with Pulmonary Hypertension associated with Interstitial Lung Disease ("PH-ILD", Group 3 PH) to expand the therapeutic breadth of TX45Ongoing TX45 APEX Phase 2 clinic

TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH‑HFrEF")TX45 was well tolerated in patients with PH‑HFrEF with no serious or severe adverse events, no clinically significant changes in blood pressure and no immune related reactionsResults support potential expansion of TX45's addressable Group 2 PH patient population to PH‑HFrEFCompany to host webcast today, October 29th at 4:30 p.m. ET WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), today announced positive topline results from the Phase 1b Part B acute hemodynami

WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in three upcoming investor conferences taking place in September 2025. 2025 Wells Fargo Healthcare Conference Date:September 3, 2025Location:Boston, MAFormat:Investor Meetings   Cantor Global Healthcare Conference Date:September 4, 2025Time:2:10 PM EDTLocation:New York, NYFormat:Fireside ChatPresenters:Daniel Lochner, Chief F

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

3 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

Raymond James upgraded Tectonic Therapeutic from Outperform to Strong Buy and set a new price target of $81.00

Stifel initiated coverage of Tectonic Therapeutic with a rating of Buy and set a new price target of $75.00

Wells Fargo initiated coverage of Tectonic Therapeutic with a rating of Overweight and set a new price target of $101.00

Oppenheimer initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $80.00

Truist initiated coverage of Tectonic Therapeutic with a rating of Buy and set a new price target of $64.00

Raymond James resumed coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $76.00

Mizuho initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $51.00

Raymond James initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $65.00

Wells Fargo initiated coverage of Tectonic Therapeutic with a rating of Overweight and set a new price target of $55.00

Piper Sandler initiated coverage of Tectonic Therapeutic with a rating of Overweight

8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

10-Q - Tectonic Therapeutic, Inc. (0001681087) (Filer)

DEFA14A - Tectonic Therapeutic, Inc. (0001681087) (Filer)

DEF 14A - Tectonic Therapeutic, Inc. (0001681087) (Filer)

8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

S-8 POS - Tectonic Therapeutic, Inc. (0001681087) (Filer)

S-8 - Tectonic Therapeutic, Inc. (0001681087) (Filer)

8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

10-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

4/A - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed Jessica Chutter to its Board of Directors, effective June 8, 2026. Ms. Chutter brings more than four decades of experience in global healthcare investment banking, with deep expertise advising biotechnology and pharmaceutical companies on strategic positioning, mergers and acquisitions, and capital markets execution. She is widely recognized as a pioneer in investment

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure ("PCWP") in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance ("PVR") in Combined pre- and post-capillary PH ("CpcPH"), a subpopulation with more severe diseaseTX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune rel

Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan

TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech

SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13G - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13G - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13D - Tectonic Therapeutic, Inc. (0001681087) (Subject)